GlassScriptPhysician profile
Daniel H Cohen
NPI 1104829779
$6,864.62
in general payments reported to CMS, 2019-2025
23 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $531 · 2021: $891 · 2022: $1,321 · 2023: $1,081 · 2024: $839 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,975 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,974.61 |
| Education | $253.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,649.04 | 2019-2025 | |
| Janssen Biotech, INC. | $1,588.54 | 2019-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $1,252.13 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $482.18 | 2019-2025 | |
| Amgen INC. | $380.06 | 2019-2025 | Tavneos, Evenity, Otezla |
| Mallinckrodt Hospital Products INC. | $216.75 | 2020-2023 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $154.11 | 2022-2023 | Orencia |
| Actelion Pharmaceuticals US, INC. | $141.44 | 2019-2024 | Opsumit, Uptravi |
| Ucb, INC. | $120.22 | 2019-2024 | Bimzelx, Cimzia |
| Radius Health, INC. | $118.94 | 2019-2023 | Tymlos |
| Horizon Therapeutics Plc | $107.38 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $103.11 | 2021-2024 | Saphnelo |
| Genentech USA, INC. | $98.18 | 2019-2024 | Actemra, Rituxan |
| Aurinia Pharma U.S., INC. | $80.23 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $79.50 | 2019-2025 | Benlysta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $76.84 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.33 | 2019-2021 | |
| Allergan, INC. | $44.74 | 2020 | |
| Janssen Pharmaceuticals, INC | $29.94 | 2025 | Tremfya |
| Depuy Synthes Sales INC. | $19.77 | 2019 | |
| Averitas Pharma INC. | $19.42 | 2023 | Qutenza |
| Lilly USA, LLC | $17.66 | 2020 | |
| Celgene Corporation | $16.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.